The Phase 3 trial of Immunocore’s bispecific therapy KIMMTRAK (tebentafusp‑tebn) enrolled 378 patients, with 252 receiving KIMMTRAK and 126 receiving investigator’s choice, 82% of whom were treated with pembrolizumab. Five‑year overall survival reached 16% for the KIMMTRAK arm compared with 8% for the control arm, a statistically significant improvement reflected by a hazard ratio of 0.67 (95% CI 0.54‑0.85). Median overall survival was 21.6 months for KIMMTRAK versus 16.9 months for investigator’s choice, and the Kaplan–Meier curves remained separated over time, indicating durable benefit.
KIMMTRAK’s performance establishes it as the first‑line standard of care for HLA‑A*02:01‑positive metastatic uveal melanoma. The data represent the longest prospective Phase 3 follow‑up for any T‑cell engager in a solid tumor, underscoring the durability of the therapeutic effect and reinforcing Immunocore’s competitive advantage in this rare but aggressive cancer.
Professor Paul Nathan, a consultant medical oncologist, noted that the 5‑year landmark data “allow us, for the first time, to speak with real confidence to patients about the possibility of long‑term survival.” The results also support Immunocore’s broader pipeline strategy, as the company explores KIMMTRAK in additional indications and advances other ImmTAC candidates.
Analysts responded positively to the extended survival data, raising price targets and highlighting the 3.6% market gain that followed the announcement. The key driver of the favorable reaction was the demonstration of a doubling of 5‑year survival rates and the sustained separation of survival curves, which validate the clinical value of KIMMTRAK and its potential to capture a larger share of the metastatic uveal melanoma market.
The long‑term survival benefit strengthens Immunocore’s market position, enhances reimbursement prospects, and provides a solid foundation for future expansion of KIMMTRAK’s reach. The data also reinforce confidence in the company’s ImmTAC platform, positioning Immunocore for continued growth in oncology and beyond.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.